Read more

September 30, 2021
1 min read
Save

Substantial variability in kidney biopsy decisions, established guidelines needed

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

When asked how the decision to perform a kidney biopsy was determined, nephrologists responded with substantial variability. According to data published in Kidney Medicine, several factors go into the decision.

Previous studies have shown biopsies can be critical for the correct treatment of patients, but there are no widely used formal guidelines for biopsy.

Biopsy tools
Source: Adobe Stock

In a qualitative study, Afolarin Amodu, MD, MPH, nephrologist at Boston Medical Center, and colleagues investigated the contemporary clinical decision-making among nephrologists regarding the decision to perform native kidney biopsy.

Researchers interviewed 20 nephrologists; 16 from academic centers, three performed their own biopsies and seven had been in practice for less than 10 years. All nephrologists were chosen with purposive sampling from different regions of the United States.

Using semi-structured interviews and open-ended questions, researchers explored the ways that nephrologists weigh clinical indications for kidney biopsy and their opinions about patient engagement in the decision-making. Nephrologists were asked to reflect on how their clinical experiences with biopsy could have impacted their practice patterns. All interviews occurred between September 2018 and October 2019.

Following the interviews, researchers found substantial variability in the way nephrologists felt about using kidney biopsy, which came down to individual differences in weighing the risks vs. benefits of the procedure for patients.

According to the study, these differences were explained by the following five main themes: comfort with biopsy and availability of interventional radiology for the procedure; experience with biopsy; concerns about biopsy risks including patient characteristics and preference; and perception of inadequate evidence base.

Limitations of this study included generalizability because the nephrologists sampled may not be broadly representative.

“We found that the biopsy decision is complex and that multiple factors inform the decision to biopsy including nephrologist’s experience with the biopsy procedure, nephrologists’ varying perspectives on indications, the ease of scheduling biopsies, and patient preference,” Amodu and colleagues wrote. “Development of consensus guidelines may assist nephrologists in making complex clinical decisions that balance risks and benefits.”